UTv Videos

The CR rate was 71% in patients with BCG-unresponsive NMIBC with CIS with or without papillary disease.

"It’s a very good time to be taking care of patients with bladder cancer," says Joshua J. Meeks, MD, PhD.

“In this well-selected patient population, it is possible to treat with systemic therapy alone," says John L. Gore, MD, MS.

“I truly think genetic testing should be incorporated as a part of daily care in prostate cancer,” says Joy Maulik, CRNP.

Hear from 5 experts as they recap some of the top data from this year's AUA.

Grace Khaner and Melissa A. Laudano, MD, share their thoughts on the potential for expanding the use of vibegron early in treatment for OAB.

DiBianco discusses findings from the Better Lithotripsy and Ureteroscopy Evaluation of Stenting trial.

“[These are] very good numbers for these patients who otherwise would undergo a radical cystectomy," says Félix Guerrero-Ramos, MD, PhD, FEBU.

The SOUL study is assessing patient-reported outcomes and unplanned health care utilization among patients who had stent placement vs stent omission after ureteroscopy.

“I think the best thing about these guidelines is their actual existence,” says Karyn S. Eilber, MD.

"To me, the key take-home is that the benefits that we see in clinical trials, we actually can replicate in the real world," says Stephen J. Freedland, MD.

“It is likely that more and more, these newer agents are going to play earlier and more central roles in the early treatment of BCG-unresponsive disease," says Shreyas S. Joshi, MD, MPH.

“It's going to be an important time for US urologists to identify that this is becoming the standard of care," says Joshua J. Meeks, MD, PhD.

Shay Rajavel, MS3, shares details on an AUA 2025 presentation on CO2 gas embolism during laparoscopic surgery.

Kevin C. Zorn, MD, FRCSC, FACS, recaps the AUA 2025 session, “State-of-the-Art Lecture: Preservation of Ejaculatory Function with BPH Treatments."

Neal D. Shore, MD, FACS, shares the background and key findings from the phase 3 CREST trial, exploring sasanlimab plus BCG for BCG-naive NMIBC.

Vitaly Margulis, MD, shares his insights on initial data from the phase 3 ENLIGHTED trial.

Joseph Jacob, MD, outlines key findings on TAR-200 monotherapy from cohort 2 of the SunRISe-1 study.

Matthew D. Galsky, MD, discusses how urologists should approach patient selection for perioperative durvalumab plus chemotherapy based on eligibility criteria for the NIAGARA trial.

The PRELUDE trial is assessing oncological outcomes with neoadjuvant 177Lu-PSMA-617 in high-risk, localized prostate cancer.

The use of onabotulinumtoxinA (onabotA, Botox) for the treatment of overactive bladder comes with several important considerations.

“Like any disease state, you want to make sure you have the right diagnosis; otherwise, you're not going to have a successful treatment plan," says Karyn S. Eilber, MD.

“We have to understand as providers that we're not going to be the one and only conduit for this information anymore, which is a good thing, to be honest," says Ian Metzler, MD, MTM.

The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey.